Inmagene Biopharmaceuticals

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

DROP DOWN LINKS TO STUDIES: Sanofi’s GEMINI 1 & 2 And HERCULES Trials In Multiple Sclerosis Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes w

DROP DOWN LINKS TO STUDIES: Sanofi’s GEMINI 1 & 2 And HERCULES Trials In Multiple Sclerosis Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes w

Pipeline candidates targeting IL-17 from Affibody AB / Acelyrin, Inc. and UCB S.A. have had positive mid- to late-stage readouts in hidradenitis suppurativa (HS), a debilitating skin condition tha